Atlas Trials

Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer

Clinical trial NCT00415636 · COMPLETED

Trial details

NCT number
NCT00415636
Sponsor
Eli Lilly and Company
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Cancer
Start date
2007-01-01
Primary completion
2010-03-01
Enrollment
31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.